Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ribo-AI

More Like This

PR Newswire associated0

Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)

PR Newswire associated0

Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange

PR Newswire associated0

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

PR Newswire associated0

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

PR Newswire associated0

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

PR Newswire associated0

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology